The stem cell therapy project Blue4Therapy brought to a highly successful close
The Blue4Therapy project was initiated in May 2020 with the ambition to develop clinical applications in cell therapy and stem cell treatments – two areas with great commercial potential for AcouSort. Behind the project were the University of Southern Denmark, BlueCell Therapeutics, Novozymes and AcouSort. AcouSort's contribution to the project has been to develop a module for the purification of stem cells in a point-of-care environment (POC). The project has now been successfully finalized and the applications and hardware that AcouSort has developed within the Blue4Therapy framework have significantly strengthened the company’s position within the cell therapy industry.
The Blue4Therapy project has allowed AcouSort to develop an application with the ability to, from a starting material containing up to 25 different types of cells, accurately and with great precision select, purify, and up-concentrate the cells needed to treat erectile dysfunction. Through AcouSort’s unique acoustic separation technology, the new application has robust up-concentration capabilities, and produces the required concentration levels of the target cells to optimize treatment success rate. The application can easily be adapted to meet the needs of other stem cell therapies – something which will be very valuable for AcouSort’s continued efforts targeting the stem cell industry.
Within the framework of the Blue4Therapy project, AcouSort has also designed and built a demonstrator device. The device is intended to be used by BlueCell to further characterize and isolate stem cells from adipose tissue. The device also provides the opportunity to evaluate integration of the AcouWash technology in third party instruments, making it a valuable tool for other potential partners and customers of AcouSort.
“The Blue4Therapy has provided AcouSort with new knowledge, a unique application for selection, purification, and concentration of cells to be used in advanced cell therapies as well as a demonstrator device that could prove very useful for AcouSort going forward. All in all, the Blue4Therapy project has significantly strengthened our cell therapy position,” says AcouSort’s CEO Torsten Freltoft.
View the video to learn more about the Blue4Therapy project: https://www.youtube.com/watch?v=Ac5B9ekmqsA
For further information on AcouSort, please contact:
Torsten Freltoft, CEO
Telephone: +45 2045 0854
E-mail: torsten.freltoft@acousort.com
About AcouSort
AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company’s Certified Adviser is Erik Penser Bank, 08-463 83 00, mail to: certifiedadviser@penser.se Erik Penser Bank AB (publ), Apelbergsgatan 27, Box 7405, 103 91 Stockholm.